Immunorejection resistant engineered cells
Patent Information
- Application Number
- CN202380028796.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-12-01
- Filing Date
- 2023-11-30
- Publication Date
- 2024-11-08
AI Technical Summary
In the case of allogeneic transplantation, exogenous transplanted cells or organs are easily recognized and attacked by immune cells in the subject, leading to immune rejection. Although existing technologies such as knocking out CD52 or HLA-I class molecules can reduce rejection, But there are issues with being costly or not entirely effective.
Provide an immunosuppressive molecule, which includes an immunosuppressive protein binding domain, a transmembrane domain and a co-stimulatory domain, but does not contain a primary signaling domain, selected from antibodies targeting FasL, IRP60, SIRPα and other antibodies or their ligands, It is used to reduce immune rejection of subject cells and suppress immune responses by expressing these molecules or related engineered cells.
It effectively reduces the immune rejection of the subject's cells against foreign cells, improves the tolerance and survival rate of the transplanted cells, and avoids some cost and efficiency problems in the existing technology.
Smart Images

Figure CN118922452A_ABST
Abstract
Description
Engineered cells resistant to immune rejection
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to Chinese patent application number 202211543531.6, entitled “Engineering cells resistant to immune rejection,” filed with the State Intellectual Property Office of China on December 1, 2022, the entire contents of which are incorporated by reference into this application. Technical Field
[0003] The present invention belongs to the field of immunotherapy. More specifically, the present invention relates to an immunosuppressive molecule comprising an immunosuppressive protein binding domain, a transmembrane domain, and a co-stimulatory domain and not comprising a primary signaling domain, wherein the immunosuppressive protein binding domain is selected from an antibody targeting FasL, an antibody targeting IRP60, a ligand of IRP60 or a functional fragment thereof, an antibody targeting SIRPα, a ligand of SIRPα or a functional fragment thereof, wherein the immunosuppressive molecule is capable of reducing immune rejection of cells in a subject. The present invention also relates to engineered cells expressing the immunosuppressive molecule, and methods for inhibiting immune rejection of cells in a subject. Background Art
[0004] In the case of allogeneic transplantation, exogenous transplanted cells or transplanted organs will be recognized and attacked by the immune cells in the subject, resulting in immune rejection. For example, when a patient receives allogeneic cell therapy (such as CAR-T cells) or organ transplantation, the normal immune system in the patient's body will reject the exogenous cells, thereby producing host-versus-graft disease (HvGD). Currently, HvGD is mainly reduced or avoided by knocking out CD52 or HLA-I class molecules. Specifically, knocking out CD52 can make CAR-T cells resistant to alemtuzumab (CD52 antibody), thereby avoiding killing the introduced CAR-T cells when alemtuzumab is used to clear T cells in the patient's body. However, the use of alemtuzumab will increase the production cost of CAR-T products. On the other hand, although knocking out HLA-I class molecules can ensure that CAR-T cells are not cleared by T cells in the patient's body without the use of antibodies or other treatments, cells with HLA-I molecules knocked out will still be recognized by other immune cells of the patient, such as NK cells, and undergo rejection reactions. Therefore, there is still a need to improve existing cell therapies, especially to reduce patients' immune rejection reactions.
[0005] Summary of the Invention
[0006] Unless otherwise defined, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0007] Immunosuppressive molecules
[0008] In a first aspect, the present invention provides an immunosuppressive molecule comprising an immunosuppressive protein binding domain, a transmembrane domain and a co-stimulatory domain and does not comprise a primary signaling domain, wherein the immunosuppressive protein binding domain is selected from an antibody targeting FasL, an antibody targeting IRP60, a ligand of IRP60 or a functional fragment thereof, an antibody targeting SIRPα, a ligand of SIRPα or a functional fragment thereof, wherein the immunosuppressive molecule is capable of reducing immune rejection of cells in a subject.
[0009] As used herein, the term "immunosuppressive molecule" refers to a molecule that can bind to immunosuppressive proteins (e.g., FasL, IRP60, SIRPα) and thereby inhibit the subject's immune rejection of foreign cells, such as reducing the killing function of immune cells (e.g., T cells, NK cells) in the subject's body or inhibiting the excessive proliferation of immune cells.
[0010] As used herein, the term "antibody" has the broadest meaning as understood by those skilled in the art, and includes monoclonal antibodies (including complete antibodies), polyclonal antibodies, multivalent antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments or synthetic polypeptides carrying one or more CDR sequences that can exhibit desired biological activity. The antibodies of the present invention can be of any class (e.g., IgG, IgE, IgM, IgD, IgA, etc.) or subclass (e.g., IgG1, IgG2, IgG2a, IgG3, IgG4, IgA1, IgA2, etc.).
[0011] As used herein, the term "antigen-binding fragment" or "antibody fragment" refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen. It has been shown that the antigen-binding function of an antibody can be achieved by fragments of a full-length antibody. Examples of antibody fragments in the present invention include, but are not limited to, Fab, Fab', F(ab')2, Fd fragments, Fd', Fv fragments, single-chain antibodies (scFv), disulfide-linked Fv (sdFv), heavy chain variable regions (VH) or light chain variable regions (VL) of antibodies, linear antibodies, "diabodies" with two antigen-binding sites, single domain antibodies (sdAb), nanobodies, and the like. Therefore, unless the context clearly indicates otherwise, the "antibody" of the present invention encompasses antibody fragments or antigen-binding fragments as defined above. Therefore, in a preferred embodiment, the antibody of the present invention is selected from IgG, Fab, Fab', F(ab')2, Fd, Fd', Fv, scFv, sdFv, linear antibodies, diabodies, sdAb or nanobodies, preferably scFv, sdAb or nanobodies.
[0012] Typically, a complete antibody consists of two heavy chains and two light chains linked together by disulfide bonds. Each light chain is connected to its own heavy chain by disulfide bonds, forming a "Y"-shaped structure. Each heavy chain comprises a heavy chain variable region (VH), which contains three complementarity-determining regions (CDRs): CDR1-H, CDR2-H, and CDR3-H, and a heavy chain constant region, which contains three constant domains: CH1, CH2, and CH3. Each light chain comprises a light chain variable region (VL), which contains three CDRs: CDR1-L, CDR2-L, and CDR3-L, and a light chain constant region, which contains one constant domain, CL. Within the heavy and light chain variable regions, the CDRs are separated by more conserved framework regions (FRs). The variable regions of the heavy and light chains are responsible for antigen recognition and binding, while the constant regions mediate the binding of the antibody to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component of the classical complement system.
[0013] The precise amino acid sequence boundaries of a given CDR or FR can be readily determined using a number of numbering schemes well known in the art, including: Kabat et al. (1991), "Sequences of Proteins of Immunological Interest," 5th ed. Public Health Service, National Institutes of Health, Bethesda, Maryland ("Kabat" numbering scheme); Al-Lazikani et al., (1997) JMB 273, 927-948 ("Chothia" numbering scheme); MacCallum et al., J. Mol. Biol. 262:732-745 (1996), "Antibody-antigen interactions: Contact analysis and binding sitetopography," J. Mol. Biol. 262, 732-745 ("Contact" numbering scheme); Lefranc MP et al., "IMGTunique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains," Dev Comp Immunol, 2003 Jan;27(1):55-77 (“IMGT” numbering scheme); Honegger A and Plückthun A, “Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool,” J Mol Biol, 2001 Jun 8;309(3):657-70 (“Aho” numbering scheme); and Martin et al., “Modeling antibody hypervariable loops: a combined algorithm,” PNAS, 1989, 86(23):9268-9272 (“AbM” numbering scheme).
[0014] In some embodiments, the boundary of CDR or FR is different depending on the scheme used to define CDR or FR. For example, the Kabat scheme is based on structural alignment, and the Chothia scheme is based on structural information. The numbering of Kabat and Chothia schemes is all based on the most common antibody region sequence length, wherein insertion (such as "30a") is provided by inserting letters and disappearance occurs in some antibodies. These two schemes are placed in different positions with certain insertions and deletions (indel), thereby producing different numbering. The Contact scheme is based on the analysis of complex crystal structure, and is similar to the Chothia numbering scheme in many aspects. The AbM scheme is a compromise between Kabat and Chothia definitions, and it is based on the scheme used by the AbM antibody modeling software of Oxford Molecular.
[0015] Therefore, unless otherwise specified, it should be understood that the "CDR" of a given antibody or its region (such as its variable region) covers the CDR defined by any of the above schemes or other known schemes. For example, when specifying that a specific CDR (such as CDR3) contains a given amino acid sequence, it should be understood that such CDR can also have the sequence of the corresponding CDR (such as CDR3) defined by any of the above schemes or other known schemes. Similarly, unless otherwise specified, it should be understood that the FR of a given antibody or its region (such as its variable region) covers the FR defined by any of the above schemes or other known schemes. Unless otherwise specified, the numbering scheme used to define the boundaries of CDR and FR in this article adopts the Chothia scheme.
[0016] In one embodiment, the antibody of the invention is a murine antibody, a chimeric antibody, a camelid antibody, a humanized antibody, or a human antibody.
[0017] In one embodiment, the immunosuppressive protein-binding domain contained in the immunosuppressive molecule of the present invention is an antibody targeting FasL. FasL is a type II cell membrane glycoprotein and a member of the tumor necrosis factor receptor superfamily (TNFRSF). FasL is distributed on the surface of activated T lymphocytes, NK cells, monocytes, and macrophages, and its ligand is Fas. The Fas / FasL system has been found to be one of the important pathways of cell apoptosis. Specifically, the binding of FasL to Fas forms a death-inducing complex, which in turn activates the caspase signaling pathway, ultimately leading to cell apoptosis through intracellular tyrosine and serine phosphorylation. It has been reported that malfunction of Fas / FasL is closely associated with various clinical diseases, such as autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.), acute immune hyperactivity (caused by organ transplantation, multiple trauma, etc.), chronic immune hyperactivity (Kawasaki disease, idiopathic pulmonary fibrosis, etc.), chronic infections (EBV infection, viral inflammation, etc.), and lymphomas (T-ALL, T-cell lymphoma, etc.).
[0018] Any anti-FasL antibody known in the art can be used in the present invention. In one embodiment, the antibody targeting FasL comprises a light chain variable region and a heavy chain variable region, wherein the CDR1-L, CDR2-L, and CDR3-L contained in the light chain variable region are identical to the CDR1-L, CDR2-L, and CDR3-L contained in SEQ ID NO: 8; and wherein the CDR1-H, CDR2-H, and CDR3-H contained in the heavy chain variable region are identical to the CDR1-H, CDR2-H, and CDR3-H contained in SEQ ID NO: 7 or 13. In one embodiment, the light chain variable region comprises CDR1-L as shown in SEQ ID NO: 4, CDR2-L as shown in SEQ ID NO: 5, and CDR3-L as shown in SEQ ID NO: 6; the heavy chain variable region comprises CDR1-H as shown in SEQ ID NO: 1, CDR2-H as shown in SEQ ID NO: 2, and CDR3-H as shown in SEQ ID NO: 3; or CDR1-H as shown in SEQ ID NO: 10, CDR2-H as shown in SEQ ID NO: 11, and CDR3-H as shown in SEQ ID NO: 12.
[0019] In one embodiment, the antibody targeting FasL comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO: 8, or has one or several (e.g., at most 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids) amino acid modifications compared to the amino acid sequence of SEQ ID NO: 8; wherein the heavy chain variable region is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO: 7 or 13, or has one or several (e.g., at most 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids) amino acid modifications compared to the amino acid sequence of SEQ ID NO: 8; NO: 7 or 13 has one or more (e.g., up to 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid) amino acid modifications compared to the amino acid sequence of SEQ ID NO: 7 or 13. Preferably, the modifications are conservative modifications, such as conservative substitutions, additions, and deletions of amino acids. In a preferred embodiment, the antibody of the present invention comprises a heavy chain variable region as set forth in SEQ ID NO: 7 or 13 and a light chain variable region as set forth in SEQ ID NO: 8.
[0020] In one embodiment, the antibody targeting FasL is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO: 9 or 14, or has one or several (e.g., at most 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids) amino acid modifications compared to the amino acid sequence of SEQ ID NO: 9 or 14. Preferably, the antibody targeting FasL is as shown in SEQ ID NO: 9 or 14.
[0021] In one embodiment, the immunosuppressive protein binding domain contained in the immunosuppressive molecule of the present invention is an antibody targeting SIRPα, a ligand of SIRPα, or a functional fragment thereof. SIRPα, also known as signal regulatory protein a or CD172a, is a transmembrane protein expressed on the surface of macrophages, dendritic cells, NK cells, and nerve cells, and its intracellular region contains an immunoreceptor tyrosine-based inhibitory motif (ITIM). The ligand of SIRPα is CD47, a cell surface protein that transmits a "don't eat me" signal on healthy cells. In addition, CD47 is also widely expressed on various tumor cells as a mechanism to evade immune detection. Many studies have found that inhibiting the CD47-SIRPα signaling pathway in cancer cells (for example, by anti-CD47 antibodies or anti-SIRPα antibodies) can promote the phagocytosis of tumor cells by macrophages, ultimately limiting tumor growth.
[0022] Any anti-SIRPα antibody known in the art can be used in the present invention. In one embodiment, the antibody targeting SIRPα comprises a light chain variable region and a heavy chain variable region, wherein the CDR1-L, CDR2-L, and CDR3-L contained in the light chain variable region are identical to the CDR1-L, CDR2-L, and CDR3-L contained in SEQ ID NO: 57; wherein the CDR1-H, CDR2-H, and CDR3-H contained in the heavy chain variable region are identical to the CDR1-H, CDR2-H, and CDR3-H contained in SEQ ID NO: 56. In one embodiment, the CDR1-L contained in the light chain variable region is as shown in SEQ ID NO: 53, the CDR2-L is as shown in SEQ ID NO: 54, and the CDR3-L is as shown in SEQ ID NO: 55; the CDR1-H contained in the heavy chain variable region is as shown in SEQ ID NO: 50, the CDR2-H is as shown in SEQ ID NO: 51, and the CDR3-H is as shown in SEQ ID NO: 52.
[0023] In one embodiment, the antibody targeting SIRPα comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO: 57, or has one or several (e.g., at most 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids) amino acid modifications compared to the amino acid sequence of SEQ ID NO: 57; wherein the heavy chain variable region is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO: 56, or has a sequence identical to SEQ ID NO: The antibody of the present invention comprises a heavy chain variable region as set forth in SEQ ID NO: 56 and a light chain variable region as set forth in SEQ ID NO: 57.
[0024] In one embodiment, the antibody targeting SIRPα is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO: 58, or has one or several (e.g., at most 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids) amino acid modifications compared to the amino acid sequence of SEQ ID NO: 58. Preferably, the antibody targeting SIRPα is as shown in SEQ ID NO: 58.
[0025] In one embodiment, the SIRPα binding domain contained in the immunosuppressive molecule of the present invention is a ligand of SIRPα, such as CD47 or a functional fragment thereof (i.e., a fragment having SIRPα binding function), such as the extracellular region of CD47. In this embodiment, the transmembrane region of the immunosuppressive molecule is preferably the CD47 transmembrane region. Preferably, the immunosuppressive molecule may also contain a portion of the CD47 intracellular region.
[0026] In one embodiment, the SIRPα ligand is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO: 69, or has one or several (e.g., at most 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids) amino acid modifications compared to the amino acid sequence of SEQ ID NO: 69. Preferably, the SIRPα ligand is as shown in SEQ ID NO: 69.
[0027] In one embodiment, the immunosuppressive protein binding domain contained in the immunosuppressive molecule of the present invention is an antibody targeting IRP60, a ligand of IRP60, or a functional fragment thereof. IRP60, also known as CD300a, is a type I transmembrane inhibitory receptor. IRP60 is widely expressed on the surface of myeloid cells (e.g., dendritic cells, mast cells, granulocytes, monocytes) and lymphocytes (T cells, B cells, etc.), and its expression level varies based on cell type and degree of differentiation. IRP60 contains four ITIMs, and the initiation of its inhibitory signal depends on the phosphorylation of tyrosine residues in the ITIMs. By interacting with ligand aminophospholipids (e.g., PtdEth and / or PtdSer), IRP60 participates in regulating various cellular activities, such as cell growth, proliferation, apoptosis, differentiation, immune response, etc. It is reported that IRP60 is closely related to the development of diseases such as hematological malignancies (e.g., leukemia, lymphoma, etc.), infectious diseases, allergic reactions, and chronic inflammatory reactions.
[0028] Any anti-IRP60 antibody known in the art can be used in the present invention, such as TX41, TX49, etc. In one embodiment, the antibody targeting IRP60 comprises a light chain variable region and a heavy chain variable region, wherein the CDR1-L, CDR2-L, and CDR3-L comprised in the light chain variable region are identical to the CDR1-L, CDR2-L, and CDR3-L comprised in SEQ ID NO: 66; and wherein the CDR1-H, CDR2-H, and CDR3-H comprised in the heavy chain variable region are identical to the CDR1-H, CDR2-H, and CDR3-H comprised in SEQ ID NO: 65. In one embodiment, the light chain variable region comprises CDR1-L as shown in SEQ ID NO: 62, CDR2-L as shown in SEQ ID NO: 63, and CDR3-L as shown in SEQ ID NO: 64; the heavy chain variable region comprises CDR1-H as shown in SEQ ID NO: 59, CDR2-H as shown in SEQ ID NO: 60, and CDR3-H as shown in SEQ ID NO: 61.
[0029] In one embodiment, the antibody targeting IRP60 comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO: 66, or has one or several (e.g., at most 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid) amino acid modifications compared to the amino acid sequence of SEQ ID NO: 66; wherein the heavy chain variable region is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO: 65, or has a sequence identical to SEQ ID NO: 66. The antibody of the present invention comprises a heavy chain variable region as set forth in SEQ ID NO: 65 and a light chain variable region as set forth in SEQ ID NO: 66.
[0030] In one embodiment, the antibody targeting IRP60 is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 67, or has one or several (e.g., at most 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids) amino acid modifications compared to the amino acid sequence of SEQ ID NO: 67. Preferably, the antibody targeting IRP60 is as set forth in SEQ ID NO: 67.
[0031] As used herein, the term "conservative modification" refers to an amino acid modification that does not significantly affect or alter the binding characteristics of an antibody or antibody fragment containing the amino acid sequence. These conservative modifications include conservative substitutions, additions, and deletions of amino acids. Modifications can be introduced into the chimeric antigen receptors of the present invention by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are substitutions in which an amino acid residue is replaced by an amino acid residue with a similar side chain. Families of amino acid residues with similar side chains have been defined in the art and include basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), β-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Conservative modifications may be selected, for example, on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or the amphipathic nature of the residues involved.
[0032] As used herein, the term sequence "identity" refers to the extent to which two (nucleotide or amino acid) sequences have the same residue at the same position in an alignment, and is usually expressed as a percentage. Preferably, identity is determined over the entire length of the sequences being compared. Thus, two copies of exactly the same sequence have 100% identity. It is known to those skilled in the art that sequence identity can be determined using algorithms such as Blast (Altschul et al. (1997) Nucleic Acids Res. 25: 3389-3402), Blast2 (Altschul et al. (1990) J. Mol. Biol. 215: 403-410), Smith-Waterman (Smith et al. (1981) J. Mol. Biol. 147: 195-197), and ClustalW.
[0033] As used herein, the term "transmembrane domain" refers to a polypeptide structure that enables expression of an immunosuppressive molecule on the cell surface and anchors the immunosuppressive protein-binding domain to the cell membrane. A transmembrane domain can be natural or synthetic and can be derived from any membrane-bound or transmembrane protein. When the target-binding domain binds to a target, the transmembrane domain enables signal transduction. Transmembrane domains particularly suitable for use in the present invention can be derived from, for example, TCRα chain, TCRβ chain, TCRγ chain, TCRδ chain, CD3ζ subunit, CD3ε subunit, CD3γ subunit, CD3δ subunit, CD28, CD45, CD4, CD5, CD8a, CD9, CD16, CD22, CD33, CD37, CD47, CD64, CD80, CD86, CD94, CD134, CD137, CD154, KIRDS2, OX40, CD2, CD27, CD18, ICOS, 4-1BB, GITR, CD40, BAFFR, HVEM, SLAMF7, NKp80, CD160, BCMA, IL-2Rβ, IL-2Rγ, IL-7R a, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CDl ld, ITGAE, CD103, ITGAL, CDl la, LFA-1, ITGAM, CDl lb, ITGAX, CDl lc, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1, SLAMF4, CD84, CD96, CEACAM1, CRT AM, Ly9, CD160, PSGL1, CDIOO, SLAMF6, SLAMF1, SLAMF8, CD162, LTBR, PAG / Cbp, NKp44, NKp30, NKp46, NKG2D or NKG2C. In some embodiments, the transmembrane domain is derived from the following molecules: CD8a, CD4, CD28, 4-1BB, CD47, CD80, CD86, CD152 and PD1. Alternatively, the transmembrane domain can be synthetic and can mainly contain hydrophobic residues such as leucine and valine. Preferably, the transmembrane domain is derived from CD28, which has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 15. Preferably, the transmembrane domain is derived from CD8a, which has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 16 or 17.
[0034] In one embodiment, the immunosuppressive molecule further comprises a hinge region between the immunosuppressive protein binding domain and the transmembrane domain. As used herein, the term "hinge region" generally refers to any oligopeptide or polypeptide that acts to connect the transmembrane domain to the antibody. Specifically, the hinge region is used to provide greater flexibility and accessibility for the antibody. The hinge region can comprise up to 300 amino acids, preferably 10 to 100 amino acids and most preferably 25 to 50 amino acids. The hinge region can be derived in whole or in part from natural molecules, such as whole or in part from the extracellular region of CD8, CD4 or CD28, or in whole or in part from an antibody constant region. Alternatively, the hinge region can be a synthetic sequence corresponding to a naturally occurring hinge sequence, or can be a fully synthetic hinge sequence. In a preferred embodiment, the hinge region comprises the hinge region portion of CD8α, CD28, FcγRIIIα receptor, IgG4 or IgG1, more preferably CD8α, CD28 or IgG4 hinge. In one embodiment, the hinge region is from CD28, which has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97%, 99% or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 27. In one embodiment, the hinge region is from CD8a, which has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97%, 99% or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 28 or 29. In one embodiment, the hinge region is from IgG4, which has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97%, 99% or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 30.
[0035] As used herein, "costimulatory domain" refers to at least a portion of a protein that mediates intracellular signal transduction to induce an immune response such as an effector function, which is an intracellular functional signaling domain from a costimulatory molecule, comprising the entire intracellular region of the costimulatory molecule, or a functional fragment thereof. "Costimulatory molecule" refers to a cognate binding partner that specifically binds to a costimulatory ligand, thereby mediating a costimulatory response (e.g., proliferation and survival). The costimulatory signaling domain of any costimulatory molecule is suitable for use in immunosuppressive molecules as described herein. Costimulatory molecules include, but are not limited to, class 1 MHC molecules, BTLA, and Toll ligand receptors. The non-limiting examples of the costimulatory domains of the present invention include but are not limited to the intracellular region derived from following protein:LTB, CD94, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, CARD11, CD2, CD7, CD8, CD18, CD27, CD28, CD30, CD40, CD54, CD83, CD134, 4-1BB, CD270, CD272, B7-H3, ICOS, CD357, DAP10, DAP12, LAT, NKG2C, SLP76, PD-1, LIGHT, TRIM, ZAP70 and their combination.Preferably, the costimulatory domains of CAR of the present invention are 4-1BB, CD28 or 4-1BB+CD28. In one embodiment, the costimulatory domain is from 4-1BB, which has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 19 or 20. In one embodiment, the costimulatory domain is from CD28, which has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 18.
[0036] The immunosuppressive molecules of the present invention do not include a primary signaling domain. As used herein, the term "primary signaling domain" refers to a protein structure that works together to trigger primary signaling after antigen-receptor binding, which is generally an intracellular sequence of a T cell receptor and a co-receptor. The primary signaling domain generally includes one or more immunoreceptor tyrosine-based activation motifs (ITAMs). Non-limiting examples of the primary signaling domain of the present invention include, but are not limited to, those derived from FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD5, CD22, CD79a, CD79b, NFAM1, STAM1, STAM2, and CD66d. In one embodiment, the immunosuppressive molecules of the present invention do not include a CD3ζ intracellular region. For example, the CD3ζ intracellular region has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97%, 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 21, 22 or 23.
[0037] In one embodiment, the immunosuppressive molecule of the present invention further comprises a signal peptide so that when it is expressed in a cell, such as a T cell, the nascent protein is directed to the endoplasmic reticulum and subsequently to the cell surface. The core of the signal peptide may contain a long hydrophobic amino acid segment that has a tendency to form a single α-helix. At the end of the signal peptide, there is usually an amino acid segment that is recognized and cleaved by a signal peptidase. The signal peptidase can cleave during or after translocation to produce a free signal peptide and a mature protein. The free signal peptide is then digested by a specific protease. Signal peptides that can be used in the present invention are well known to those skilled in the art, such as signal peptides derived from B2M, CD8α, IgG1, GM-CSFRα, etc. In one embodiment, the signal peptide that can be used in the present invention is derived from B2M and has a sequence identity of at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97%, 99%, or 100% to the amino acid sequence shown in SEQ ID NO: 24. In one embodiment, the signal peptide useful in the present invention is derived from CD8a and has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97%, 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 25 or 26.
[0038] Nucleic acids and vectors
[0039] The present invention also provides a nucleic acid molecule comprising a nucleic acid sequence encoding the immunosuppressive molecule of the present invention. Optionally, the nucleic acid molecule may further comprise a nucleic acid sequence encoding a functional exogenous receptor (e.g., a chimeric antigen receptor, a chimeric T cell receptor, etc.).
[0040] As used herein, the term "nucleic acid molecule" includes sequences of ribonucleotides and deoxyribonucleotides, such as modified or unmodified RNA or DNA, each in single-stranded and / or double-stranded form, linear or circular, or mixtures thereof (including hybrid molecules). Thus, nucleic acids according to the present invention include DNA (such as dsDNA, ssDNA, cDNA), RNA (such as dsRNA, ssRNA, mRNA, ivtRNA), combinations thereof, or derivatives thereof (such as PNA). Preferably, the nucleic acid is DNA or RNA.
[0041] Nucleic acids may comprise conventional phosphodiester bonds or unconventional bonds (such as amide bonds, such as those found in peptide nucleic acids (PNA)). The nucleic acids of the present invention may also contain one or more modified bases, such as, for example, tritylated bases and uncommon bases (such as inosine). Other modifications are also contemplated, including chemical, enzymatic or metabolic modifications, as long as the multi-chain CAR of the present invention can be expressed from polynucleotides. Nucleic acids may be provided in an isolated form. In one embodiment, nucleic acids may also include regulatory sequences, such as transcriptional control elements (including promoters, enhancers, operators, repressors, and transcription termination signals), ribosome binding sites, introns, and the like.
[0042] The nucleic acid sequences of the present invention can be codon-optimized for optimal expression in desired cells (e.g., immune cells); or for expression in bacteria, yeast, or insect cells. Codon optimization refers to replacing codons present in the target sequence that are generally rare in highly expressed genes of a given species with codons that are generally common in highly expressed genes of such species, with the codons before and after the replacement encoding the same amino acid. Therefore, the selection of the optimal codon depends on the codon usage preference of the host genome.
[0043] The present invention also provides a vector comprising the nucleic acid molecule of the present invention. Optionally, the nucleic acid sequence encoding the immunosuppressive molecule and the nucleic acid sequence encoding the functional exogenous receptor (e.g., chimeric antigen receptor, chimeric T cell receptor, etc.) can be located on the same vector or different vectors.
[0044] As used herein, the term "vector" is used as a mediating nucleic acid molecule for transferring (exogenous) genetic material to a host cell, wherein the nucleic acid molecule can, for example, be replicated and / or expressed. Suitable vectors that can be used for the present invention are known in the art, and many are commercially available. In one embodiment, vectors of the present invention include, but are not limited to, plasmids, viruses (such as retroviruses, adenoviruses, adeno-associated viruses, vaccinia viruses, vesicular stomatitis viruses, measles viruses, mumps viruses, polioviruses, orthomyxoviruses, parvoviruses, Maraba viruses, coxsackie viruses, herpes viruses, and slow viruses, etc.), bacteriophages, phagemids, cosmids, and artificial chromosomes (including BACs and YACs). Vectors are generally also included in the starting point (if stable expression of polynucleotides is desired) for autonomous replication in cells, selective markers, and restriction enzyme cleavage sites (such as multiple cloning sites, MCSs). Vectors can additionally include elements such as promoters, polyadenylic acid tails (polyA), 3'UTRs, enhancers, terminators, insulators, operators, selective markers, reporter genes, targeting sequences, and / or protein purification tags. In a specific embodiment, the vector is an in vitro transcribed vector.
[0045] Engineered cells
[0046] The present invention also provides an engineered cell that expresses the immunosuppressive molecule of the present invention, a nucleic acid encoding the immunosuppressive molecule, or a vector comprising the nucleic acid. In one embodiment, the engineered cell of the present invention also expresses a functional exogenous receptor (as defined below).
[0047] In one embodiment, the engineered cells of the invention are engineered immune cells.
[0048] As used herein, the term "immune cell" refers to any cell with one or more effector functions (e.g., cytotoxic cell killing activity, secretion of cytokines, induction of ADCC and / or CDC) of the immune system. For example, immune cell can be a B cell, a T cell, a macrophage, a dendritic cell, a monocyte, a NK cell or a NKT cell. Immune cell can be obtained from a variety of sources, for example, from a subject (e.g., from subject's peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from infection site, ascites, pleural effusion, spleen tissue, tumor etc.), or from a cell line (e.g., Jurkat, SupT1, NK92 etc.) cultured in vitro, or from stem cell differentiation (e.g., derived from cord blood stem cells, progenitor cells, bone marrow stem cells, hematopoietic stem cells, adult stem cells, embryonic stem cells, pluripotent stem cells, iPSC etc.). Preferably, immune cell is a T cell or a NK cell, more preferably a T cell. T cell can also be concentrated or purified. T cells can be in any developmental stage, including but not limited to, CD4+CD8+T cells, CD4+T cells (e.g., Th1 and Th2 cells), CD8+T cells (e.g., cytotoxic T cells), CD4-CD8-T cells, tumor infiltrating cells, memory T cells, immature T cells, γδ-T cells, αβ-T cells, etc. In a preferred embodiment, the immune cells are human T cells. T cells can be obtained from the blood of a subject using a variety of techniques known to those skilled in the art, such as Ficoll separation.
[0049] In one embodiment, the expression of at least one endogenous HLA-I class gene of the engineered cells of the present invention is suppressed or silenced. In one embodiment, the expression of at least one endogenous HLA-II class gene of the engineered cells of the present invention is suppressed or silenced. In one embodiment, the expression of at least one endogenous TCR / CD3 gene of the engineered cells of the present invention is suppressed or silenced. In one embodiment, the expression of at least one endogenous TCR / CD3 gene and at least one endogenous HLA-I class gene of the engineered cells of the present invention is suppressed or silenced. In one embodiment, the expression of at least one endogenous TCR / CD3 gene, at least one endogenous HLA-I class gene, and at least one endogenous HLA-II class gene of the engineered cells of the present invention is suppressed or silenced. Preferably, the HLA-I class gene is selected from HLA-A, HLA-B, HLA-C, and B2M. Preferably, the HLA-II class gene is selected from HLA-DPA, HLA-DQ, HLA-DRA, TAP1, TAP2, LMP2, LMP7, RFX5, RFXAP, RFXANK and CIITA, preferably selected from RFX5, RFXAP, RFXANK and CIITA. Preferably, the TCR / CD3 gene is selected from TRAC, TRBC, CD3γ, CD3δ, CD3ε and CD3ζ.
[0050] In one embodiment, the expression of one or more endogenous genes selected from the group consisting of CD52, GR, dCK, and immune checkpoint genes such as PD1, LAG3, TIM3, CTLA4, PPP2CA, PPP2CB, PTPN6, PTPN22, PDCD1, HAVCR2, BTLA, CD160, TIGIT, CD96, CRTAM, TNFRSF10B, TNFRSF10A, CASP8, and CASP10 is suppressed or silenced in the engineered cells of the present invention. , CASP3, CASP6, CASP7, FADD, FAS, TGFBRII, TGFBRRI, SMAD2, SMAD3, SMAD4, SMAD10, SKI, SKIL, TGIF1, IL10RA, I L10RB, HMOX2, IL6R, IL6ST, EIF2AK4, CSK, PAG1, SIT, FOXP3, PRDM1, BATF, GUCY1A2, GUCY1A3, GUCY1B2 and GUCY1B3.
[0051] Methods for inhibiting gene expression or silencing genes are well known to those skilled in the art, including but not limited to, for example, DNA or RNA breakage mediated by large-range nucleases, zinc finger nucleases, TALENs, CRISPR / Cas systems, base editors, or gene inactivation by antisense oligonucleotides, RNAi, shRNA, transposons, mutations, and the like.
[0052] In one embodiment, the engineered cells of the present invention are allogeneic cells. As used herein, the term "allogeneic" refers to any material derived from a different animal or patient of the same species as the individual into which the material is introduced. Two or more individuals are considered allogeneic to each other when the genes at one or more loci are different. In some cases, allogeneic material from individuals of the same species may differ genetically enough to cause antigenic interaction.
[0053] Functional xenobiotic receptors
[0054] In one embodiment, the engineered cells expressing immunosuppressive molecules of the present invention may also express a functional exogenous receptor. Preferably, the functional exogenous receptor is selected from a recombinant T cell receptor, a chimeric antigen receptor, a T cell fusion protein, or a T cell antigen coupler, more preferably a chimeric antigen receptor.
[0055] As used herein, the term "T cell fusion protein" or "TFP" refers to a recombinant polypeptide derived from various components of a TCR, typically consisting of a TCR subunit and an antibody linked thereto, and expressed on the cell surface. The TCR subunit includes at least a portion of the TCR extracellular domain, the transmembrane domain, and the TCR intracellular signaling domain.
[0056] As used herein, the term "T cell antigen coupler" or "TAC" includes three functional domains: 1. a tumor targeting domain, including a single-chain antibody (such as the anti-FasL antibody, anti-IRP60 antibody or anti-SIRPα antibody of the present invention), a designed ankyrin repeat protein (DARPin) or other targeting groups; 2. an extracellular domain, a single-chain antibody that binds to CD3, thereby bringing the TAC receptor into proximity with the TCR receptor; 3. a transmembrane region and an intracellular region of the CD4 co-receptor, wherein the intracellular region is connected to the protein kinase LCK, catalyzing the phosphorylation of the immunoreceptor tyrosine-based activation motif (ITAM) of the TCR complex as the initial step of T cell activation.
[0057] As used herein, the term "T cell receptor" or "TCR" is a characteristic marker on the surface of T cells, which binds to CD3 with a non-covalent bond to form a complex. Antigen presenting cells present antigen peptides to T cells through major histocompatibility complex molecules (MHC) and bind to the TCR complex to induce a series of intracellular signal transductions. TCR consists of six peptide chains that form heterodimers, which are generally divided into αβ type and γδ type. Each peptide chain includes a constant region and a variable region, wherein the variable region is responsible for binding to specific antigens and MHC molecules. The term "recombinant TCR receptor" refers to an artificially constructed T cell receptor that further comprises an antigen (e.g., tumor antigen) binding domain.
[0058] As used herein, the term "chimeric antigen receptor" or "CAR" refers to an artificially constructed hybrid polypeptide that generally includes an antigen (e.g., tumor antigen) binding domain (e.g., a ligand for an antibody or antigen), a transmembrane domain, an optional costimulatory domain, and a primary signaling domain, with each domain connected by a linker. CAR is capable of redirecting the specificity and reactivity of T cells and other immune cells to a selected target in a non-MHC restricted manner. In one embodiment, the functional exogenous receptor of the present invention is a chimeric antigen receptor comprising a tumor antigen binding domain, a transmembrane domain, one or more costimulatory domains, and a primary signaling domain. In one embodiment, the chimeric antigen receptor further comprises one or more of the following structures: a signal peptide, a hinge region, a suicide gene, a switch structure, and the like.
[0059] In one embodiment, the functional exogenous receptor comprises an extracellular domain that specifically recognizes an antigen (e.g., a tumor antigen). In one embodiment, the extracellular domain comprises an antibody that specifically binds to an antigen or a ligand for the antigen. In one embodiment, the antigen is selected from the group consisting of ALK, ADRB3, AKAP-4, APRIL, ASGPR1, BCMA, B7H3, B7H4, B7H6, bcr-abl, BORIS, BST2, BAFF-R, BTLA, CD2, CD3, CD4, CD5, CD7, CD8, CD19, CD20, CD22, CD24, CD25, CD28, CD30, CD33, CD38, CD40, CD44, CD44v6, CD44v7 / 8, CD47, CD52, CD56, CD57, CD58, CD70, CD72, CD79a, CD79b, CD80, CD81, CD86, CD97, CD123, CD133, CD137, CD 138, CD151, CD171, CD179a, CD300LF, CLEC12A, CDH16, CSPG4, CS1, CLL-1, Claudin 6, Claudin18.1, Claudin 18.2, CEA, CEACAM6, c-Met, CAIX, CXORF61, CA125, CYP1B1, CS1, ELF2M, EGFR, EPCAM, EGFRvIII, EphA2, ERG / TMPRSS2ETS fusion gene, ETV6-AML, EMR2, EGP2,EGP40, FAP, FAR, FBP, FLT3, FOSL1, FCRL5, FCAR, Flt3, Flt4, Frizzled, GD2, GD3, gp100, gp130, GM3, GPC2, GPC3, GPRC5D, GPR20, GloboH, GHRHR, GHR, GITR, Her2, HER3, HER-4, HMWMAA, HAVCR1, HPV E6,E7, HVEM, HIV-1Gag, HLA-A1, HLA-A2, IL6R, IL-11Ra, IL-13Ra, IGF-I receptor, LTPR, LIFRP, LRP5, IGLL1, IGF1R, KIT, Kappa Light Chain, KDR, LewisY, LMP2, LY6K, LAGE-1a, legumain, LCK, LAIR1, LILRA2, LY75, MSLN, MUC1, MUC16, MAGE-A1, MAGE3, MAD-CT-1, MelanA / MART1, ML-IAP, MYCN, mut hsp70-2, NCAM, NY-BR-1, NY-ESO-1, NA17, Notch-1-4, nAchR, NKG2D, NKG2D ligand, OY-TES1, OR51E2, OX40, PRSS21, PSCA, PD1, PD-L1, PD-L2, PSMA, Prostase, PAP, PDGFR-β, PCTA-1 / galectin 8, p53, p53 mutant, prostein, PLAC1, PANX3, PAX3, PAX5, PTCH1, RANK, RAGE-1, ROR1, Ras mutant, RhoC, RU1, RU2, Robol, SSEA-4, SSX2, SART3, Sp17, TSHR, Tn Ag, TGS5, TEM1 / CD248, TEM7R, TARP, TCRα, TCRβ, TGFBR1, TGFBR2, TNFRSF4, TWEAK-R, TLR7, TLR9, TAG72, TROP-2, Tie 2, TRP-2, TNFR1, TNFR2, TEM1, UPK2 VEGFR, WT1, XAGE1, 5T4, 8H9, αvβ6 integrin, CA9, folate receptor α, ephrin B2, tyrosinase, fucosyl GM1, o-acetyl-GD2, folate receptor β, polysialic acid, sperm protein 17, survivin and telomerase, sarcoma translocation breakpoints, human telomerase / hTERT, androgen receptor, intestinal carboxylesterase, cyclin B1, fibronectin, tenascin, oncofetal variants of tumor necrosis, or any combination thereof. Preferably,The antigen is selected from CD7, CD19, CD20, CD22, CD30, CD33, CD38, CD123, CD138, CD171, MUC1, MSLN, AFP, folate receptor α, CEA, PSCA, PSMA, Her2, EGFR, IL-13Ra, GD2, NKG2D, Claudin18.2, ROR1, EGFRvIII, CS1, BCMA and GPRC5D, more preferably selected from CD19, Claudin18.2, MSLN, GPRC5D, CD7 and BCMA.
[0060] In one embodiment, the functional exogenous receptor comprises an extracellular domain that specifically recognizes CD19, such as an antibody targeting CD19. In one embodiment, the antibody targeting CD19 comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises CDR1-L as shown in SEQ ID NO: 35, CDR2-L as shown in SEQ ID NO: 36, and CDR3-L as shown in SEQ ID NO: 37; and the heavy chain variable region comprises CDR1-H as shown in SEQ ID NO: 32, CDR2-H as shown in SEQ ID NO: 33, and CDR3-H as shown in SEQ ID NO: 34.
[0061] In one embodiment, the antibody targeting CD19 comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO: 39, 41 or 43, or has one or several (e.g., at most 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids) amino acid modifications compared to the amino acid sequence of SEQ ID NO: 39, 41 or 43; wherein the heavy chain variable region is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO: 38, 40 or 42, or has a heavy chain variable region that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO: The antibody of the present invention comprises a heavy chain variable region as set forth in SEQ ID NO: 38, 40 or 42 and a light chain variable region as set forth in SEQ ID NO: 39, 41 or 43.
[0062] In one embodiment, the antibody targeting CD19 is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO: 44, 45, 46, 47 or 48, or has one or several (e.g., at most 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids) amino acid modifications compared to the amino acid sequence of SEQ ID NO: 44, 45, 46, 47 or 48. Preferably, the antibody targeting FasL is as shown in SEQ ID NO: 44, 45, 46, 47 or 48.
[0063] In one embodiment, the functional exogenous receptor of the present invention is a chimeric antigen receptor comprising an antigen binding domain, a transmembrane domain, one or more costimulatory domains, and a primary signaling domain. In one embodiment, the functional exogenous receptor of the present invention is a chimeric antigen receptor that targets CD19, CD7, CD19, CD20, CD22, CD30, CD33, CD38, CD123, CD138, CD171, MUC1, MSLN, AFP, folate receptor α, CEA, PSCA, PSMA, Her2, EGFR, IL-13Ra, GD2, NKG2D, Claudin18.2, ROR1, EGFRvIII, CS1, BCMA, or GPRC5D, more preferably targeting CD19, Claudin18.2, MSLN, ROR1, GPRC5D, CD7, and BCMA. In one embodiment, the chimeric antigen receptor further comprises a signal peptide, a hinge region, or both. The definitions of the transmembrane domain, co-stimulatory domain, primary signaling domain, and optional hinge region, signal peptide, etc. of the CAR that can be used in the present invention are described in the "Immunosuppressive Molecules" section above.
[0064] In one embodiment, the CAR of the present invention may further comprise a switch structure to regulate the expression time of CAR. For example, the switch structure may be in the form of a dimerization domain, which causes a conformational change by binding to its corresponding ligand, exposing the extracellular binding domain so that it binds to the targeted antigen, thereby activating the signal transduction pathway. Alternatively, the switch domain may be used to connect the binding domain and the signal transduction domain respectively, and only when the switch domains bind to each other (for example, in the presence of an inducing compound) can the binding domain and the signal transduction domain be connected together through a dimer, thereby activating the signal pathway. The switch structure may also be in the form of a masking peptide. The masking peptide may shield the extracellular binding domain, preventing it from binding to the targeted antigen, and when the masking peptide is cleaved by, for example, a protease, the extracellular binding domain may be exposed, making it a "normal" CAR structure. Various switch structures known to those skilled in the art may be used in the present invention.
[0065] In one embodiment, the CAR of the present invention may also include a suicide gene, that is, it is expressed by a cell death signal that can be induced by an exogenous substance, so as to remove the CAR cells when needed (for example, when serious toxic side effects are produced). For example, the suicide gene can be in the form of an inserted epitope, such as a CD20 epitope, RQR8, etc., and when needed, the CAR cells can be eliminated by adding antibodies or reagents targeting these epitopes. The suicide gene can also be herpes simplex virus thymidine kinase (HSV-TK), which can cause cells to die under the induction of ganciclovir treatment. The suicide gene can also be iCaspase-9, which can be induced by chemical induction drugs such as AP1903, AP20187, etc. to dimerize iCaspase-9, thereby activating downstream Caspase3 molecules, leading to apoptosis. Various suicide genes known to those skilled in the art can be used in the present invention.
[0066] Pharmaceutical composition
[0067] The present invention also provides a pharmaceutical composition comprising the immunosuppressive molecule, engineered cell, nucleic acid molecule, or vector described herein as an active agent and one or more pharmaceutically acceptable excipients. Therefore, the present invention also encompasses the use of the immunosuppressive molecule, nucleic acid molecule, vector, or engineered cell in the preparation of a pharmaceutical composition or medicament.
[0068] As used herein, the term "pharmaceutically acceptable excipient" refers to a carrier and / or excipient that is pharmacologically and / or physiologically compatible with the subject and the active ingredient (i.e., capable of inducing the desired therapeutic effect without causing any undesirable local or systemic effects), which is well known in the art (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995). Examples of pharmaceutically acceptable excipients include, but are not limited to, fillers, binders, disintegrants, coatings, adsorbents, antiadherents, glidants, antioxidants, flavorings, colorants, sweeteners, solvents, cosolvents, buffers, chelating agents, surfactants, diluents, wetting agents, preservatives, emulsifiers, coatings, isotonic agents, absorption delaying agents, stabilizers, and tension modifiers. It is known to those skilled in the art to select suitable excipients to prepare the pharmaceutical compositions desired in the present invention. Exemplary excipients for use in the pharmaceutical compositions of the present invention include saline, buffered saline, glucose, and water. In general, the choice of suitable excipients depends on, inter alia, the active agent used, the disease to be treated and the desired dosage form of the pharmaceutical composition.
[0069] The pharmaceutical composition according to the present invention can be applied in a variety of ways. Typically, administration is accomplished parenterally. Parenteral delivery methods include topical, intra-arterial, intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, intrauterine, intravaginal, sublingual, or intranasal administration.
[0070] The pharmaceutical composition according to the present invention can also be prepared in various forms, such as solid, liquid, gaseous or lyophilized forms, particularly in the form of ointments, creams, transdermal patches, gels, powders, tablets, solutions, aerosols, granules, pills, suspensions, emulsions, capsules, syrups, elixirs, extracts, tinctures or fluid extracts, or in a form particularly suitable for the desired method of administration. The processes known in the present invention for producing drugs may include, for example, conventional mixing, dissolving, granulating, sugar coating, grinding, emulsifying, encapsulating, embedding or lyophilizing processes. Pharmaceutical compositions comprising, for example, immune cells as described herein are typically provided in solution form and preferably comprise a pharmaceutically acceptable buffer.
[0071] The pharmaceutical composition according to the present invention can also be used in combination with one or more other medicaments (biological agents such as antibody reagents, and / or small molecules) or therapeutic methods (such as surgery, chemotherapy or radiotherapy) that are applicable to the treatment and / or prevention of the disease to be treated. Preferred examples of the medicament suitable for combination include known anticancer drugs, such as cisplatin, maytansine derivatives, rachelmycin (rachelmycin), calicheamicin (calicheamicin), docetaxel, etoposide, gemcitabine, ifosfamide, irinotecan, melphalan, mitoxantrone, sorfimer sodium porphyrin II (sorfimer sodium photofrin II), temozolomide, topotecan, trimetreate glucuronate (trimetreate glucuronate), auristatin E (auristatin E), vincristine and doxorubicin; peptide cytotoxins such as ricin, diphtheria toxin, Pseudomonas exotoxin A, DNA enzymes and RNA enzymes; radionuclides such as iodine-131, rhenium-186, indium-111, iridium-90, bismuth-210 and 213, actinium-225 and astatine-213; prodrugs such as antibody-directed enzyme prodrugs; immunostimulants such as platelet factor 4 and melanoma growth stimulating protein; antibodies or fragments thereof such as anti-CD3 antibodies or fragments thereof, complement activators, heterologous protein domains, homologous protein domains, viral / bacterial protein domains and viral / bacterial peptides. In addition, the pharmaceutical compositions of the present invention can also be used in combination with one or more other treatment methods, such as chemotherapy and radiotherapy.
[0072] In one embodiment, the pharmaceutical compositions of the present invention are used to treat a subject suffering from cancer, infection, or autoimmune disease.
[0073] In one embodiment, the cancer is a cancer associated with expression of a target to which a functional exogenous receptor binds. For example, the cancer includes, but is not limited to, brain gliomas, blastomas, sarcomas, leukemias, basal cell carcinomas, biliary tract cancer, bladder cancer, bone cancer, brain and CNS cancers, breast cancer, peritoneal cancer, cervical cancer, choriocarcinoma, colon and rectal cancer, connective tissue cancer, cancers of the digestive system, endometrial cancer, esophageal cancer, eye cancer, head and neck cancer, gastric cancer (including gastrointestinal cancer), glioblastoma (GBM), liver cancer, hepatoma, intraepithelial neoplasia, kidney cancer, laryngeal cancer, liver tumors, lung cancers (e.g., small cell lung cancer, non-small cell lung cancer, adenocarcinoma and squamous lung cancer), lymphoma (including Hodgkin lymphoma and non-Hodgkin lymphoma), melanoma, myeloma, neuroblastoma, oral cancer (e.g., lip, tongue, mouth, and pharynx), ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, rectal cancer, cancers of the respiratory system, salivary gland cancer, skin cancer, squamous cell carcinoma, stomach cancer, testicular cancer, thyroid cancer, uterine or endometrial cancer, malignancies of the urinary system, vulvar cancer, and other carcinomas and sarcomas, and B-cell lymphomas (including low-grade / follicular non-Hodgkin lymphoma (NHL) ), small lymphocytic (SL) NHL, intermediate-grade / follicular NHL, intermediate-grade diffuse NHL, high-grade immunoblastic NHL, high-grade lymphoblastic NHL, high-grade small non-cleaved cell NHL, large mass disease NHL), mantle cell lymphoma, AIDS-related lymphoma, and Waldenstrom macroglobulinemia, chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), B-cell acute lymphoblastic leukemia (B-ALL), T-cell acute lymphoblastic leukemia (T-ALL), B-cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, chronic myeloid leukemia (CML), malignant lymphoproliferative disease, MALT lymphoma, hairy cell leukemia, marginal zone lymphoma, multiple myeloma, myelodysplasia, plasmablastic lymphoma, preleukemia, plasmacytoid dendritic cell neoplasm, and post-transplantation lymphoproliferative disorder (PTLD); and other diseases related to target expression. Preferably, the diseases that can be treated with the engineered immune cells or pharmaceutical compositions of the present invention are selected from: leukemia, lymphoma, multiple myeloma, brain glioma, pancreatic cancer, gastric cancer, etc.
[0074] In one embodiment, the infection includes, but is not limited to, infections caused by viruses, bacteria, fungi, and parasites.
[0075] In one embodiment, the autoimmune diseases include but are not limited to type I diabetes, celiac disease, Graves' disease, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, Addison's disease, Sjögren's syndrome, Hashimoto's thyroiditis, myasthenia gravis, vasculitis, pernicious anemia and systemic lupus erythematosus.
[0076] Method for inhibiting immune rejection of foreign cells by immune cells of a subject
[0077] In one aspect, the present invention also provides a method for reducing immune rejection of exogenous cells by cells of a subject, characterized in that the immunosuppressive molecule of the present invention, the nucleic acid molecule encoding the immunosuppressive molecule or the vector containing the nucleic acid molecule is expressed in the exogenous cells.
[0078] In another aspect, the present invention also provides a method for reducing immune rejection of exogenous cells by cells in a subject, characterized in that the immunosuppressive molecule of the present invention or the engineered cell expressing the immunosuppressive molecule is administered to the subject. In one embodiment, the immunosuppressive molecule or engineered cell of the present invention is administered simultaneously or sequentially with the exogenous cell. For example, the immunosuppressive molecule or engineered cell of the present invention can be administered after the exogenous cell.
[0079] As used herein, the term "subject" is a mammal. The mammal can be a human, non-human primate, mouse, rat, dog, cat, pig, horse, or cow, but is not limited to these examples. Mammals other than humans can be advantageously used as subjects representing animal models of cancer. Preferably, the subject is a human.
[0080] The present invention will be described in detail below with reference to the accompanying drawings and in conjunction with examples. It should be noted that those skilled in the art should understand that the accompanying drawings and embodiments of the present invention are for illustrative purposes only and do not constitute any limitation to the present invention. The embodiments and features in the embodiments of the present application may be combined with each other unless there is any contradiction. BRIEF DESCRIPTION OF THE DRAWINGS
[0081] FIG1 shows the CAR expression levels of CAR-T cells expressing an immunosuppressive molecule targeting FasL.
[0082] FIG2 shows the killing effect of CAR-T cells expressing immunosuppressive molecules targeting FasL on target cells.
[0083] FIG3 shows the cytokine release levels after co-incubation of CAR-T cells expressing immunosuppressive molecules targeting FasL with target cells Nalm6.
[0084] FIG4 shows the cytokine release levels after CAR-T cells expressing immunosuppressive molecules targeting FasL were co-incubated with target cells Raji.
[0085] FIG5 shows the inhibitory effect of immunosuppressive molecules targeting FasL on the proliferation of allogeneic PBMCs.
[0086] FIG6 shows the in vivo tumor-suppressive effect of CAR-T cells expressing immunosuppressive molecules targeting FasL.
[0087] FIG. 7 shows the CAR expression levels of CAR-T cells expressing an immunosuppressive molecule targeting SIRPα.
[0088] FIG. 8 shows the expression level of anti-SIRPα antibodies in CAR-T cells expressing immunosuppressive molecules targeting SIRPα.
[0089] FIG9 shows the cytokine release levels after CAR-T cells expressing immunosuppressive molecules targeting SIRPα were co-incubated with target cells Nalm6.
[0090] FIG10 shows the cytokine release levels after CAR-T cells expressing immunosuppressive molecules targeting SIRPα were co-incubated with target cells Raji.
[0091] FIG. 11 shows the inhibitory effect of immunosuppressive molecules targeting SIRPα on NK cell killing.
[0092] FIG. 12 shows the CAR expression levels of CAR-T cells expressing immunosuppressive molecules targeting IRP60.
[0093] FIG. 13 shows the expression levels of anti-IRP60 antibodies in CAR-T cells expressing immunosuppressive molecules targeting IRP60.
[0094] FIG14 shows the cytokine release levels after co-incubation of CAR-T cells expressing immunosuppressive molecules targeting IRP60 with target cells Nalm6.
[0095] FIG15 shows the cytokine release levels after co-incubation of CAR-T cells expressing immunosuppressive molecules targeting IRP60 with target cells Raji.
[0096] FIG. 16 shows the inhibitory effect of immunosuppressive molecules targeting IRP60 on NK cell killing.
[0097] FIG. 17 shows the CAR expression levels of CAR-T cells expressing immunosuppressive molecules including CD47.
[0098] FIG. 18 shows the expression level of CD47 in CAR-T cells expressing immunosuppressive molecules including CD47.
[0099] FIG. 19 shows the killing effect of CAR-T cells expressing immunosuppressive molecules including CD47 on target cells Raji.
[0100] FIG20 shows the cytokine release levels after CAR-T cells expressing immunosuppressive molecules including CD47 were co-incubated with target cells Raji.
[0101] FIG. 21 shows the inhibitory effect of immunosuppressive molecules including CD47 on NK cell killing. DETAILED DESCRIPTION
[0102] Example 1. Construction of CAR-T immune cells expressing immunosuppressive molecules
[0103] The following coding sequences were synthesized and cloned into the pGEM-T Easy vector (Promega) in sequence: anti-CD19 scFv (SEQ ID NO: 44), CD8α hinge region (SEQ ID NO: 29), CD8α transmembrane region (SEQ ID NO: 17), 4-1BB co-stimulatory domain (SEQ ID NO: 20), CD3ζ intracellular region (SEQ ID NO: 23) to obtain the CAR19 plasmid, and the correct insertion of the target sequence in the plasmid was confirmed by sequencing.
[0104] The above-mentioned CAR19 plasmid was further expressed with an immunosuppressive molecule connected by T2A (SEQ ID NO: 31), whose structure was as follows: B2m signal peptide (SEQ ID NO: 24), anti-FasL scFv-1 (SEQ ID NO: 9) or anti-FasL scFv-2 (SEQ ID NO: 14), IgG4 hinge region (SEQ ID NO: 30), CD28 transmembrane region (SEQ ID NO: 15), CD28 costimulatory domain (SEQ ID NO: 18), to obtain CAR19-aFL-1 plasmid and CAR19-aFL-2 plasmid, and the correct insertion of the target sequence in the plasmid was confirmed by sequencing.
[0105] The following structures connected by T2A (SEQ ID NO: 31) were further expressed in the above-mentioned CAR19 plasmid: B2m signal peptide (SEQ ID NO: 24), Fas extracellular region and transmembrane region (SEQ ID NO: 49), IgG4 hinge region (SEQ ID NO: 30), CD28 transmembrane region (SEQ ID NO: 15), CD28 costimulatory domain (SEQ ID NO: 18) to obtain CAR19-Fas plasmid, and the correct insertion of the target sequence in the plasmid was confirmed by sequencing.
[0106] After diluting the plasmid in 3 ml of Opti-MEM (Gibco) in a sterile tube, the packaging vector psPAX2 (Addgene) and the envelope vector pMD2.G (Addgene) were added at a ratio of 4:2:1 between plasmid:viral packaging vector:viral envelope vector. Next, 120 μl of X-treme GENE HP DNA transfection reagent (Roche) was added, mixed immediately, and incubated at room temperature for 15 minutes. The plasmid / vector / transfection reagent mixture was then added dropwise to the 293T cell culture flask. Viruses were collected at 24 and 48 hours, pooled, and concentrated by ultracentrifugation (25,000 g, 4°C, 2.5 hours).
[0107] T cells were activated with DynaBeads CD3 / CD28 CTSTM (Gibco) and cultured for 1 day at 37°C and 5% CO2. On the next day, concentrated lentivirus was added, and after 3 days of culture, T cells expressing CD19 CAR (CAR19-T) and T cells expressing CD19 CAR + a combination of immunosuppressive molecules targeting FasL (CAR19-Fas T, CAR19-aFL-1 T, and CAR19-aFL-2 T) were obtained.
[0108] In addition, flow cytometry was used to detect the expression of anti-CD19 scFv in CAR-T cells using FITC goat anti-human Fab (Thermo Fisher). It can be seen that the CAR in the CAR-T cells prepared in this example can be effectively expressed (Figure 1).
[0109] Example 2. CAR-T cell killing effect on target cells and cytokine release level
[0110] 1×10 4Target Raji cells were plated into 96-well plates at a concentration of 10 cells / well. NT cells, CAR19 T cells, CAR19-Fas T cells, CAR19-aFL-1 T cells, and CAR19-aFL-2 T cells were then plated into 96-well plates at an effector-target ratio of 4:1, 2:1, 1:1, or 0.5:1 for co-culture. After 18 hours, fluorescence values were measured using a microplate reader. The killing efficiency was calculated according to the formula: (target cell fluorescence mean - sample fluorescence mean) / target cell fluorescence mean × 100%, and the results are shown in Figure 2.
[0111] It can be seen that CAR19-Fas T cells, CAR19-aFL-1 T cells and CAR19-aFL-2 T cells effectively kill target cells, and at a low efficiency target ratio (e.g., 0.5:1), their killing effect is slightly better than that of CAR19 T cells that do not express immunosuppressive molecules.
[0112] In addition, 1×10 5 Target cells (Nalm6 cells and Raji cells) were plated in a 96-well plate at a concentration of 1 cell / well, and NT cells, CAR19 T cells, CAR19-Fas T cells, CAR19-aFL-1 T cells, and CAR19-aFL-2 T cells were added at a ratio of 1:1. After co-culture for 18-24 hours, the cell co-culture supernatant was collected.
[0113] The levels of IL-2 and IFN-γ in the co-culture supernatants were measured using the Human IL-2 DuoSet ELISA Kit (R&D Systems) and the Human IFN-gamma DuoSet ELISA Kit (R&D Systems), respectively. The results are shown in Figures 3 and 4. As can be seen, compared with NT cells, the release of IL-2 and IFN-γ by various CAR-T cells co-cultured with target cells was significantly increased, indicating that this cytokine release is specific. Furthermore, the cytokine release levels of various CAR-T cells were essentially equivalent.
[0114] These data indicate that additional expression of immunosuppressive molecules targeting FasL does not alter the cytokine release levels of CAR-T cells and slightly enhances the in vitro killing activity of CAR-T cells at low efficiency target ratios.
[0115] Example 3. In vitro HvGD
[0116] The inhibitory effect of the immunosuppressive molecule of the present invention on HvGD in vitro was evaluated by one-way mixed lymphocyte reaction (MLR) assay. Specifically, NT cells, CAR19 T cells, CAR19-Fas T cells, CAR19-aFL-1 T cells, and CAR19-aFL-2 T cells were incubated with allogeneic PBMCs at 37 ° C and 5% CO2 for 7 days, and then the proliferation of PBMCs was detected by flow cytometry. The results are shown in Figure 5.
[0117] It can be seen that compared with NT cells, CAR19 T cells increased the count of PBMCs by about 3.5 times (0.4x10 6 vs1.4x10 6 ), indicating that heterologous CAR-T cells greatly promoted the proliferation of PBMCs. In addition, it was noted that the additional expression of immunosuppressive molecules could significantly reduce this proliferation of PBMCs. In particular, it is worth noting that the immunosuppressive molecule containing the Fas extracellular domain (CAR19-Fas T) reduced the proliferation of PBMCs by approximately 35% (approximately 0.9x10 6 ), while the immunosuppressive molecules containing anti-FasL scFv (CAR19-aFL-1 T and CAR19-aFL-2 T) further reduced the proliferation of PBMCs by about 3 times (about 0.3x10 6 ), which is basically equivalent to the effect of NT cells that do not express CAR.
[0118] In summary, the additional expression of an immunosuppressive molecule targeting FasL can significantly inhibit the proliferation of allogeneic PBMCs in vitro, thereby significantly reducing HvGD. Moreover, the inhibitory effect of the immunosuppressive molecule containing the anti-FasL scFv is significantly better than that of the immunosuppressive molecule containing the Fas extracellular domain.
[0119] Example 4. In vivo inhibitory effect of CAR T cells on tumors
[0120] Twenty-five healthy female NPI mice aged 6-8 weeks were divided into five groups, with five mice in each group: NT group, CAR19 group, CAR19-Fas group, CAR19-aFL-1 group, and CAR19-aFL-2 group. On day 0, each mouse was injected with 5×10 5 After 6 days, 2x10 Raji cells were injected into the tail vein of each mouse according to the grouping situation. 6 The mice were then assessed weekly. The mouse survival curves are shown in Figure 6.
[0121] It can be seen that the survival rate of the CAR19-Fas group is comparable to that of the CAR19 group, indicating that the immunosuppressive molecule containing the Fas extracellular domain may not exert a good immune rejection inhibitory effect in vivo. In contrast, the survival rates of the CAR19-aFL-1 and CAR19-aFL-2 groups were significantly higher than those of the CAR19-Fas group, indicating that the immunosuppressive molecule containing the anti-FasL scFv can also effectively inhibit immune rejection in vivo, thereby enhancing the tumor suppression effect of CAR-T cells and improving survival rate.
[0122] Example 5. Construction of CAR-T cells expressing immunosuppressive molecules targeting SIRPα and verification of their function
[0123] 5.1 Construction of CAR-T cells
[0124] CAR-T cells expressing immunosuppressive molecules targeting SIRPα were constructed according to the method of Example 1, wherein the B2M gene in the T cells was knocked out using the CRISPR / Cas9 system before the lentiviral transfection step. The immunosuppressive molecule targeting SIRPα comprises: B2m signal peptide (SEQ ID NO: 24), anti-SIRPα scFv (SEQ ID NO: 58), IgG4 hinge region (SEQ ID NO: 30), CD28 transmembrane region (SEQ ID NO: 15), and CD28 costimulatory domain (SEQ ID NO: 18). The obtained CAR-T cells were named CAR19-αT cells.
[0125] Using flow cytometry, FITC goat anti-human Fab (Thermo Fisher) was used to detect the expression of anti-CD19 scFv in CAR-T cells, and Human SIRPα protein (Acro) was used to detect the expression of anti-SIRPα scFv. It can be seen that the CAR in the CAR-T cells prepared in this example can be effectively expressed (Figure 7), and the immunosuppressive molecules in CAR19-α T cells can also be effectively expressed (Figure 8).
[0126] 5.2 Detection of cytokine release levels after co-incubation with target cells
[0127] 1×10 5 Target cells (Nalm6 cells and Raji cells) were plated in a 96-well plate at a concentration of 1 cell / well, and CAR19-T cells, CAR19-αT cells, and NT cells (negative control) were added at a ratio of 1:1. After co-culture for 18-24 hours, the cell co-culture supernatant was collected.
[0128] The Human IL-2 DuoSet ELISA Kit (R&D systems) and the Human IFN-gamma DuoSet ELISA Kit (R&D systems) were used to detect the levels of IL2 and IFN-γ in the co-culture supernatant, and the results are shown in Figures 9 and 10. It can be seen that compared with NT cells, the release levels of cytokines IL2 and IFN-γ by CAR19-T and CAR19-αT cells co-cultured with each target cell were significantly increased, indicating that this cytokine release is specific. In addition, the cytokine release levels of CAR19-T and CAR19-αT cells are comparable, indicating that the additional expression of immunosuppressive molecules does not impair the cytokine release characteristics of CAR-T cells.
[0129] 5.3 Detection of the inhibitory effect on NK cell killing
[0130] The CAR-T cells prepared in this example were labeled with Far-Red (Invitrogen). 4 Labeled CAR-T cells were plated into 96-well plates at a concentration of 10 cells / well and co-cultured with peripheral blood-derived allogeneic NK cells (pNK-1 and pNK-2) at a 2:1 effector-target ratio (NK cell: CAR-T cell). After 16-18 hours, the survival rate of T cells in the culture was assessed by flow cytometry. The results are shown in Figure 11.
[0131] It can be seen that compared with conventional CAR19-T cells, the survival rate of CAR19-αT cells expressing immunosuppressive molecules after co-culture with NK cells was significantly improved. This shows that the immunosuppressive molecules of the present invention can effectively inhibit the killing effect of NK cells on CAR-T cells expressing them. This is particularly effective in reducing immune rejection reactions.
[0132] Example 6. Construction of CAR-T cells expressing immunosuppressive molecules targeting IRP60 and verification of their function
[0133] 6.1 Construction of CAR-T cells
[0134] CAR-T cells expressing an immunosuppressive molecule targeting IRP60 were constructed according to the method of Example 1, wherein the B2M gene in the T cells was knocked out using the CRISPR / Cas9 system before the lentiviral transfection step. The immunosuppressive molecule targeting IRP60 comprises: a B2m signal peptide (SEQ ID NO: 24), an anti-IRP60 scFv (SEQ ID NO: 67), an IgG4 hinge region (SEQ ID NO: 30), a CD28 transmembrane region (SEQ ID NO: 15), and a CD28 costimulatory domain (SEQ ID NO: 18). The obtained CAR-T cells were named CAR19-60T cells.
[0135] Using flow cytometry, FITC goat anti-human Fab (Thermo Fisher) was used to detect the expression of anti-CD19 scFv in CAR-T cells, and Human IRP60 protein (Kactus) was used to detect the expression of anti-IRP60 scFv. It can be seen that the CAR in the CAR-T cells prepared in this example can be effectively expressed (Figure 12), and the immunosuppressive molecules in CAR19-60 T cells can also be effectively expressed (Figure 13).
[0136] 6.2 Detection of cytokine release levels after co-incubation with target cells
[0137] The release levels of cytokines IL2 and IFN-γ after the CAR-T cells prepared in this example were co-incubated with target cells Nalm6 cells and Raji cells were detected according to the method described in Example 5.2. The results are shown in Figures 14 and 15. It can be seen that compared with NT cells, the release levels of cytokines IL2 and IFN-γ after CAR19-T and CAR19-60 T were significantly increased after co-culture with each target cell, indicating that this cytokine release is specific. In addition, the cytokine release levels of CAR19-T and CAR19-60 T cells are comparable, indicating that the additionally expressed immunosuppressive molecules do not impair the cytokine release of CAR-T cells.
[0138] 6.3 Detection of the inhibitory effect on NK cell killing
[0139] The inhibitory effect of the CAR-T cells prepared in this example on the killing effect of allogeneic NK cells was detected according to the method described in Example 5.3. The results are shown in Figure 16.
[0140] It can be seen that compared with conventional CAR19-T cells, the survival rate of CAR19-60T cells expressing immunosuppressive molecules after co-culture with NK cells was significantly improved. This shows that the immunosuppressive molecules of the present invention can effectively inhibit the killing effect of NK cells on CAR-T cells expressing them.
[0141] Example 7. Construction of CAR-T immune cells expressing immunosuppressive molecules including CD47 and verification of their function
[0142] 7.1 Construction of CAR-T cells
[0143] The following coding sequences were synthesized and cloned into the pGEM-T Easy vector (Promega, Catalog No. A1360) in sequence: anti-CD19 scFv (SEQ ID NO: 44), CD8α hinge region (SEQ ID NO: 29), CD8α transmembrane region (SEQ ID NO: 17), 4-1BB co-stimulatory domain (SEQ ID NO: 20), CD3ζ intracellular region (SEQ ID NO: 23) to obtain the CAR19 plasmid, and the correct insertion of the target sequence in the plasmid was confirmed by sequencing.
[0144] The above-mentioned CAR19 plasmid was further expressed with an immunosuppressive molecule connected by T2A (SEQ ID NO: 31), whose structure was as follows: CD47 extracellular transmembrane region (SEQ ID NO: 68), CD28 costimulatory domain (SEQ ID NO: 18), to obtain the CAR19-47 plasmid, and the correct insertion of the target sequence in the plasmid was confirmed by sequencing.
[0145] After diluting the plasmid in 3 ml of Opti-MEM (Gibco, Catalog No. 31985-070) in a sterile tube, add the packaging vector psPAX2 (Addgene, Catalog No. 12260) and the envelope vector pMD2.G (Addgene, Catalog No. 12259) at a ratio of 4:2:1. Next, add 120 μl of X-treme GENE HP DNA Transfection Reagent (Roche, Catalog No. 06366236001), mix immediately, and incubate at room temperature for 15 minutes. The plasmid / vector / transfection reagent mixture is then added dropwise to the 293T cell culture flask. Viruses are harvested at 24 and 48 hours, pooled, and concentrated by ultracentrifugation (25,000 g, 4°C, 2.5 hours).
[0146] T cells were activated with DynaBeads CD3 / CD28 CTS™ (Gibco, Cat. No. 40203D) and cultured for 1 day at 37°C and 5% CO2. Concentrated lentivirus was then added, and after 3 days of culture, CD19CAR-expressing T cells (CAR19-T) and CD19CAR-expressing T cells (CAR19-47-T) that target immunosuppressive molecules targeting SIRPα were obtained.
[0147] In addition, flow cytometry was used to detect anti-CD19 scFv expression in CAR-T cells using FITC goat anti-human Fab (Thermo Fisher, Catalog No. 31628), and CD47 expression was detected using mouse anti-human CD47 Ab (Biolegend, Catalog No. 323108). It can be seen that the CAR in the CAR-T cells prepared by the present invention can be effectively expressed (Figure 17), and the immunosuppressive molecules in CAR19-CD47-T cells can also be effectively expressed (Figure 18).
[0148] 7.2 Detecting the Killing Effect of CAR-T Cells on Target Cells
[0149] 1×10 4 Target Raji cells were plated into 96-well plates at a concentration of 10 cells / well. NT cells, CAR19-T cells, and CAR19-47-T cells were then plated into 96-well plates at an effector-target ratio of 4:1, 2:1, 1:1, or 0.5:1. After 18 hours, fluorescence values were measured using a microplate reader. The killing efficiency was calculated according to the formula: (target cell fluorescence mean - sample fluorescence mean) / target cell fluorescence mean × 100%. The results are shown in Figure 19.
[0150] It can be seen that both CAR19-T cells and CAR19-47-T cells showed effective specific killing of target cells, and the killing activity of CAR19-47-T cells was significantly improved compared with CAR19-T.
[0151] 7.3. Detection of Cytokine Release Levels After Co-incubation of CAR-T Cells with Target Cells
[0152] 1×10 5 Target cells (Raji cells) were plated in a 96-well plate at a concentration of 10 cells / well, and CAR19-T cells, CAR19-CD47-T cells, and NT cells (negative control) were added at a ratio of 1:1. After co-culture for 18-24 hours, the cell co-culture supernatant was collected.
[0153] The levels of IL2 and IFN-γ in the co-culture supernatant were detected using Human IL-2 DuoSet ELISA Kit (R&D systems, Catalog No. DY202) and Human IFN-gamma DuoSet ELISA Kit (R&D systems, Catalog No. DY285), respectively. The results are shown in Figure 20.
[0154] It can be seen that compared with NT cells, the release levels of cytokines IL2 and IFN-γ were significantly increased after CAR19-T and CAR19-47-T were co-cultured with target cells, indicating that this cytokine release is specific. In addition, the secretion capacity of IFN-γ by CAR19-CD47-T cells was significantly higher than that of CAR19-T cells.
[0155] 7.4. Detection of the inhibitory effect of immunosuppressive molecules on NK cell cytotoxicity
[0156] The CAR-T cells prepared by the present invention were labeled with Far-Red (Invitrogen, Catalog No. C34564). 4 Labeled CAR-T cells were plated into 96-well plates at a concentration of 10 cells / well and co-cultured with peripheral blood-derived NK cells at a 2:1 effector-target ratio. After 16-18 hours, the survival rate of T cells in the culture was measured by flow cytometry. The results are shown in Figure 21.
[0157] It can be seen that compared with conventional CAR19-T cells, the survival rate of CAR19-47 cells expressing immunosuppressive molecules after co-culture with NK cells was significantly improved. This shows that the immunosuppressive molecules of the present invention can effectively inhibit the killing effect of NK cells on CAR-T cells.
[0158] In summary, the immunosuppressive molecules targeting FasL, IRP60 or SIRPα of the present invention will not adversely affect the killing activity or cytokine release characteristics of CAR-T cells on the one hand, and on the other hand can significantly inhibit the killing of allogeneic NK cells or inhibit the excessive proliferation of allogeneic PBMCs after activation, thereby effectively reducing the immune rejection of foreign cells by immune cells in the host body.
[0159] It should be noted that the above are merely preferred embodiments of the present invention and are not intended to limit the present invention. Those skilled in the art will readily appreciate that various modifications and variations of the present invention are possible. Those skilled in the art will appreciate that any modifications, equivalent substitutions, and improvements made within the spirit and principles of the present invention are intended to be within the scope of protection of the present invention. Industrial Applicability
[0160] The present invention relates to an immunosuppressive molecule comprising an immunosuppressive protein binding domain, a transmembrane domain, and a co-stimulatory domain, and excluding a primary signaling domain, wherein the immunosuppressive protein binding domain is selected from an antibody targeting FasL, an antibody targeting IRP60, a ligand of IRP60 or a functional fragment thereof, an antibody targeting SIRPα, a ligand of SIRPα or a functional fragment thereof, wherein the immunosuppressive molecule is capable of reducing immune rejection of cells in a subject. The immunosuppressive molecule of the present invention effectively reduces immune rejection of foreign cells by immune cells in a host body and has excellent industrial applicability.
Claims
1. An immunosuppressive molecule comprising an immunosuppressive protein binding domain, a transmembrane domain, and a co-stimulatory domain and not comprising a primary signaling domain, wherein the immunosuppressive protein binding domain is selected from an antibody targeting FasL, an antibody targeting IRP60, a ligand of IRP60 or a functional fragment thereof, an antibody targeting SIRPα, a ligand of SIRPα or a functional fragment thereof, wherein the immunosuppressive molecule is capable of reducing immune rejection of cells in a subject.
2. The immunosuppressive molecule of claim 2, wherein the antibody is selected from the group consisting of a whole antibody, Fab, Fab', F(ab')2, Fv fragment, scFv, linear antibody, sdAb or nanobody.
3. The immunosuppressive molecule of any one of claims 1 to 2, wherein the transmembrane domain is selected from the transmembrane domains of the following proteins: TCRα chain, TCRβ chain, TCRγ chain, TCRδ chain, CD3ζ subunit, CD3ε subunit, CD3γ subunit, CD3δ subunit, CD28, CD45, CD4, CD5, CD8a, CD9, CD16, CD22, CD33, CD37, CD47, CD64, CD80, CD86, CD94, CD134, CD137, CD154, KIRDS2, OX40, CD2, CD27, CD18, ICOS, 4-1BB, GITR, CD40, BAFFR, HVEM, SLAMF7, NKp80, CD160, BCMA, IL-2Rβ, IL-2Rγ, IL-7R a, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CDl ld, ITGAE, CD103, ITGAL, CDl la, LFA-1, ITGAM, CDl lb, ITGAX, CDl lc, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1, SLAMF4, CD84, CD96, CEACAM1, CRT AM, Ly9, CD160, PSGL1, CDIOO, SLAMF6, SLAMF1, SLAMF8, CD162, LTBR, PAG / Cbp, NKp44, NKp30, NKp46, NKG2D or NKG2C.
4. The immunosuppressive molecule of any one of claims 1 to 3, wherein the costimulatory domain is selected from the intracellular region of the following proteins: LTB, CD94, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, CARD11, CD2, CD7, CD8, CD18, CD27, CD28, CD30, CD40, CD54, CD83, CD134, 4-1BB, CD270, CD272, B7-H3, ICOS, CD357, DAP10, DAP12, LAT, NKG2C, SLP76, PD-1, LIGHT, TRIM, ZAP70, and combinations thereof.
5. The immunosuppressive molecule of any one of claims 1 to 4, wherein the primary signaling domain is selected from the intracellular region of the following proteins: FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD5, CD22, CD79a, CD79b, NFAM1, STAM1, STAM2, and CD66d. The immunosuppressive molecule according to any one of claims 1 to 5 , further comprising a signal peptide.
7. The immunosuppressive molecule of any one of claims 1 to 6, further comprising a hinge region derived from CD8α, CD28, FcγRIIIα receptor, IgG4, or IgG1.
8. The immunosuppressive molecule of any one of claims 1 to 7, wherein the immunosuppressive protein binding domain is an antibody targeting FasL.
9. The immunosuppressive molecule of claim 8, wherein the FasL-targeting antibody comprises a light chain variable region and a heavy chain variable region, wherein the CDR1-L, CDR2-L, and CDR3-L comprised in the light chain variable region are identical to the CDR1-L, CDR2-L, and CDR3-L comprised in SEQ ID NO: 8; and wherein the CDR1-H, CDR2-H, and CDR3-H comprised in the heavy chain variable region are identical to the CDR1-H, CDR2-H, and CDR3-H comprised in SEQ ID NO: 7 or 13; Preferably, the CDR1-L is shown in SEQ ID NO: 4, CDR2-L is shown in SEQ ID NO: 5, CDR3-L is shown in SEQ ID NO: 6, CDR1-H is shown in SEQ ID NO: 1 or 10, CDR2-H is shown in SEQ ID NO: 2 or 11, and CDR3-H is shown in SEQ ID NO: 3 or 12; Preferably, the light chain variable region is as shown in SEQ ID NO: 8, and the heavy chain variable region is as shown in SEQ ID NO: 7 or 13; Preferably, the antibody targeting FasL is shown as SEQ ID NO: 9 or 14. 10 . The immunosuppressive molecule of claim 1 , wherein the immunosuppressive protein binding domain is an antibody targeting SIRPα, a ligand of SIRPα, or a functional fragment thereof.
11. The immunosuppressive molecule of claim 10, wherein the antibody targeting SIRPα comprises a light chain variable region and a heavy chain variable region, wherein the CDR1-L, CDR2-L, and CDR3-L comprised in the light chain variable region are identical to the CDR1-L, CDR2-L, and CDR3-L comprised in SEQ ID NO: 57; and wherein the CDR1-H, CDR2-H, and CDR3-H comprised in the heavy chain variable region are identical to the CDR1-H, CDR2-H, and CDR3-H comprised in SEQ ID NO: 56; Preferably, the CDR1-L is shown in SEQ ID NO: 53, CDR2-L is shown in SEQ ID NO: 54, CDR3-L is shown in SEQ ID NO: 55, CDR1-H is shown in SEQ ID NO: 50, CDR2-H is shown in SEQ ID NO: 51, and CDR3-H is shown in SEQ ID NO: 52; Preferably, the light chain variable region is as shown in SEQ ID NO: 57, and the heavy chain variable region is as shown in SEQ ID NO: 56; Preferably, the antibody targeting SIRPα is as shown in SEQ ID NO:
58.
12. The immunosuppressive molecule of claim 10, wherein the ligand of SIRPα is CD47 or its extracellular region; Preferably, the ligand of SIRPα is shown as SEQ ID NO:
69.
13. The immunosuppressive molecule of claim 1, wherein the immunosuppressive protein binding domain is an antibody targeting IRP60, a ligand of IRP60, or a functional fragment thereof.
14. The immunosuppressive molecule of claim 13, wherein the antibody targeting IRP60 comprises a light chain variable region and a heavy chain variable region, wherein the CDR1-L, CDR2-L, and CDR3-L comprised in the light chain variable region are identical to the CDR1-L, CDR2-L, and CDR3-L comprised in SEQ ID NO: 66; and wherein the CDR1-H, CDR2-H, and CDR3-H comprised in the heavy chain variable region are identical to the CDR1-H, CDR2-H, and CDR3-H comprised in SEQ ID NO:
65. Preferably, the CDR1-L is shown in SEQ ID NO: 64, CDR2-L is shown in SEQ ID NO: 63, CDR3-L is shown in SEQ ID NO: 62, CDR1-H is shown in SEQ ID NO: 59, CDR2-H is shown in SEQ ID NO: 60, and CDR3-H is shown in SEQ ID NO: 61; Optionally, the light chain variable region is as shown in SEQ ID NO: 66, and the heavy chain variable region is as shown in SEQ ID NO: 65; Preferably, the antibody targeting IRP60 is as shown in SEQ ID NO:
67.
15. A nucleic acid molecule encoding the immunosuppressive molecule according to any one of claims 1 to 14. A vector comprising the nucleic acid molecule according to claim 15 .
17. The vector of claim 15, wherein the vector is selected from the group consisting of a retrovirus, an adenovirus, an adeno-associated virus, a vaccinia virus, a vesicular stomatitis virus, a measles virus, a mumps virus, a poliovirus, an orthomyxovirus, a parvovirus, a Maraba virus, a coxsackievirus, a herpes virus, and a lentivirus.
18. An engineered cell expressing the immunosuppressive molecule according to any one of claims 1 to 14, the nucleic acid molecule according to claim 15, or the vector according to any one of claims 16 to 17.
19. The engineered cell of claim 18, further characterized in that: The engineered cells also express functional exogenous receptors.
20. The engineered cell of claim 19, wherein the functional exogenous receptor is selected from the group consisting of a chimeric antigen receptor, a chimeric T cell receptor, a T cell antigen coupler, and a T cell fusion protein, preferably a chimeric antigen receptor.
21. The engineered cell of claim 19, wherein the functional exogenous receptor comprises an extracellular domain that specifically recognizes an antigen.
22. The engineered cell of claim 21, wherein the extracellular domain comprises an antibody that specifically recognizes the antigen or a ligand for the antigen.
23. The engineered cell of claim 22, wherein the antigen is selected from the group consisting of ALK, ADRB3, AKAP-4, APRIL, ASGPR1, BCMA, B7H3, B7H4, B7H6, bcr-abl, BORIS, BST2, BAFF-R, BTLA, CD2, CD3, CD4, CD5, CD7, CD8, CD19, CD20, CD22, CD24, CD25, CD28, CD30, CD33, CD38, CD40, CD44, CD44v6, CD44v7 / 8, CD47, CD52, CD56, CD57, CD58, CD70, CD72, CD79a, CD79b, CD80, CD81, CD86, CD97, CD123, CD133, CD137, CD 138. CD151, CD171, CD179a, CD300LF, CLEC12A, CDH16, CSPG4, CS1, CLL-1, Claudin 6, Claudin18.1, Claudin 18.2, CEA, CEACAM6, c-Met, CAIX, CXORF61, CA125, CYP1B1, CS1, ELF2M, EGFR, EPCAM, EGFRvIII, EphA2, ERG / TMPRSS2ETS fusion gene, ETV6-AML, EMR2, EGP2, EGP40, FAP, FAR, FBP, F LT3, FOSL1, FCRL5, FCAR, Flt3, Flt4, Frizzled, GD2, GD3, gp100, gp130, GM3, GPC2, GPC3, GPRC5D, GPR20, GloboH, GHRHR, GHR, GITR, Her2, HER3, HER-4, HMWMAA, HAVCR1, HPV E6,E7, HVEM, HIV-1Gag, HLA-A1, HLA-A2, IL6R, IL-11Ra, IL-13Ra, IGF-I receptor, LTPR, LIFRP, LRP5, IGLL1, IGF1R, KIT, Kappa Light Chain, KDR, LewisY, LMP2, LY6K, LAGE-1a, legumain, LCK, LAIR1, LILRA2, LY75, MSLN, MUC1, MUC16, MAGE-A1, MAGE3, MAD-CT-1, MelanA / MART1, ML-IAP, MYCN, mut hsp70-2, NCAM, NY-BR-1, NY-ESO-1, NA17, Notch-1-4, nAchR, NKG2D, NKG2D ligand, OY-TES1, OR51E2, OX40, PRSS21, PSCA, PD1, PD-L1, PD-L2, PSMA, Prostase, PAP, PDGFR-β, PCTA-1 / galectin 8, p53, p53 mutant, prostein, PLAC1, PANX3, PAX3, PAX5, PTCH1, RANK, RAGE-1, ROR1, Ras mutant, RhoC, RU1, RU2, Robol, SSEA-4, SSX2, SART3, Sp17, TSHR, Tn Ag, TGS5, TEM1 / CD248, TEM7R, TARP, TCRα, TCRβ, TGFBR1, TGFBR2, TNFRSF4, TWEAK-R, TLR7, TLR9, TAG72, TROP-2, Tie 2, TRP-2, TNFR1, TNFR2, TEM1, UPK2 VEGFR, WT1, XAGE1, 5T4, 8H9, αvβ6 integrin, CA9, folate receptor α, ephrin B2, tyrosinase, fucosyl GM1, o-acetyl-GD2, folate receptor β, polysialic acid, sperm protein 17, survivin and telomerase, sarcoma translocation breakpoints, human telomerase / hTERT, androgen receptor, intestinal carboxylesterase, cyclin B1, fibronectin, tenascin, oncofetal variant of tumor necrosis, or any combination thereof.
24. The engineered cell of claim 23, wherein the functional exogenous receptor is a chimeric antigen receptor that targets CD19, CD7, CD19, CD20, CD22, CD30, CD33, CD38, CD123, CD138, CD171, MUC1, MSLN, AFP, folate receptor alpha, CEA, PSCA, PSMA, Her2, EGFR, IL-13Ra, GD2, NKG2D, Claudin18.2, ROR1, EGFRvIII, CS1, BCMA, or GPRC5D.
25. The engineered cell of any one of claims 18-24, wherein expression of at least one endogenous HLA class I gene of the engineered cell is inhibited or silenced.
26. The engineered cell of claim 25, wherein the endogenous HLA-I class gene is selected from the group consisting of HLA-A, HLA-B, HLA-C, and B2M.
27. The engineered cell of any one of claims 18-26, wherein expression of at least one endogenous HLA class II gene of the engineered cell is inhibited or silenced.
28. The engineered cell of claim 27, wherein the endogenous HLA class II gene is selected from the group consisting of HLA-DPA, HLA-DQ, HLA-DRA, TAP1, TAP2, LMP2, LMP7, RFX5, RFXAP, RFXANK, and CIITA.
29. The engineered cell of any one of claims 18-28, wherein expression of at least one endogenous TCR / CD3 gene of the engineered cell is inhibited or silenced.
30. The engineered cell of claim 29, wherein the TCR / CD3 gene is selected from the group consisting of TRAC, TRBC, CD3γ, CD3δ, CD3ε, CD3ζ, and combinations thereof.
31. The engineered cell of any one of claims 18-30, further characterized in that: wherein the expression of one or more endogenous genes selected from the group consisting of CD52, GR, dCK, PD1, LAG3, TIM3, CTLA4, PPP2CA, PPP2CB, PTPN6, PTPN22, PDCD1, HAVCR2, BTLA, CD160, TIGIT, CD96, CRTAM, TNFRSF10B, TNFRSF10A, CASP8, CASP10, CASP3, CASP6, CASP7, FADD, FAS, TGFBRII, TGFRBRI, SMAD2, SMAD3, SMAD4, SMAD10, SKI, SKIL, TGIF1, IL10RA, IL10RB, HMOX2, IL6R, IL6ST, EIF2AK4, CSK, PAG1, SIT, FOXP3, PRDM1, BATF, GUCY1A2, GUCY1A3, GUCY1B2, and GUCY1B3 is inhibited or silenced.
32. The engineered cell of any one of claims 18-31, wherein the engineered cell is a B cell, a T cell, a macrophage, a dendritic cell, a monocyte, a NK cell, or a NKT cell.
33. The engineered immune cell of claim 32, wherein the engineered cell is a CD4+CD8+T cell, a CD4+T cell, a CD8+T cell, a CD4-CD8-T cell, a tumor infiltrating cell, a memory T cell, a naive T cell, a γδ-T cell, or an αβ-T cell.
34. The engineered cell of any one of claims 18-33, wherein the engineered cell is derived from umbilical cord blood stem cells, progenitor cells, bone marrow stem cells, hematopoietic stem cells, adult stem cells, embryonic stem cells, pluripotent stem cells, or iPSCs.
35. A method for reducing immune rejection of foreign cells by cells of a subject, characterized in that: The immunosuppressive molecule according to any one of claims 1 to 14, the nucleic acid molecule according to claim 15, or the vector according to any one of claims 16 to 17 is expressed in the exogenous cells.
36. A method for reducing immune rejection of foreign cells by cells of a subject, characterized in that: The immunosuppressive molecule of any one of claims 1 to 14 or the engineered cell of any one of claims 18 to 34 is administered to the subject.
37. A pharmaceutical composition comprising the immunosuppressive molecule of any one of claims 1-14, the nucleic acid molecule of claim 15, the vector of any one of claims 16-17 or the engineered immune cell of any one of claims 18-34, and one or more pharmaceutically acceptable excipients.
38. The pharmaceutical composition of claim 37, wherein the pharmaceutical composition is used to treat cancer, infection, or autoimmune disease.
Citation Information
Cited By
Compositions and methods for cellular immunotherapy
CN118891290A
Composition and method of cellular immunotherapy
WO2025214498A1
